Sarepta Therapeutics Inc. (NASDAQ:SRPT) has been assigned a $41.00 price target by stock analysts at Credit Suisse Group AG in a note issued to investors on Monday. The brokerage currently has a a “buy” rating on the stock. Credit Suisse Group AG’s price target indicates a potential upside of 8.21% from the company’s previous close.

Several other research analysts also recently commented on the stock. Robert W. Baird reiterated an “outperform” rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a report on Friday, November 4th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, November 2nd. RBC Capital Markets reiterated an “outperform” rating and issued a $106.00 target price (down previously from $108.00) on shares of Sarepta Therapeutics in a report on Friday, October 28th. Piper Jaffray Cos. reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Thursday, October 27th. Finally, Royal Bank Of Canada dropped their price objective on shares of Sarepta Therapeutics to $106.00 and set an “outperform” rating on the stock in a report on Friday, October 28th. One analyst has rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $66.28.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 37.89 on Monday. The firm’s market capitalization is $2.07 billion. The stock’s 50 day moving average price is $48.69 and its 200 day moving average price is $30.45. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Thursday, October 27th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.37. During the same quarter in the prior year, the company posted ($1.25) earnings per share. On average, analysts predict that Sarepta Therapeutics will post ($4.31) EPS for the current fiscal year.

In other news, insider Sandesh Mahatme sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, October 17th. The shares were sold at an average price of $50.08, for a total transaction of $1,502,400.00. Following the transaction, the insider now directly owns 61,532 shares in the company, valued at $3,081,522.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David T. Howton sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total transaction of $420,000.00. Following the transaction, the senior vice president now owns 28,453 shares in the company, valued at $1,707,180. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the company. BlackRock Fund Advisors raised its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the last quarter. State Street Corp raised its position in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares during the last quarter. Commonwealth Equity Services Inc bought a new position in shares of Sarepta Therapeutics during the second quarter worth about $302,000. National Planning Corp raised its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the last quarter. Finally, TIAA CREF Investment Management LLC raised its position in shares of Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares during the last quarter. Institutional investors own 65.91% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.